Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Beauty Press Releases.
Press releases published on April 28, 2025
UNice Hair Debuts Global Brand Ambassador Program for Gen Z Creators & Student Entrepreneurs
EIN Presswire
·
April 28, 2025
INGLEWOOD, CA, UNITED STATES, April 28, 2025 /EINPresswire.com/ -- UNice Hair, a global leader in premium-quality wigs and hair extensions, proudly introduces its Brand Ambassador Program — a dynamic new initiative designed to support and empower the …
Ocean Drive Plastic Surgery Welcomes Board Certified Plastic Surgeon, Dr. Edgar Sosa, D.O., F.A.C.S.
EIN Presswire
·
April 28, 2025
Board-certified plastic surgeon Dr. Edgar Sosa now seeing patients at Ocean Drive Plastic Surgery for breast, body, and post-weight loss procedures. VERO BEACH, FL, UNITED STATES, April 28, 2025 /EINPresswire.com/ -- Ocean Drive Plastic Surgery, …
Osmosis Launches Limited-Edition Summer Cooling Enzyme Mask for Skincare Professionals
EIN Presswire
·
April 28, 2025
Watermelon-Infused Formula Offers Seasonal Skincare Solution with Exclusive April Promotion NEW YORK CITY, NY, UNITED STATES, April 28, 2025 /EINPresswire.com/ -- Osmosis, a leading professional skincare brand, announces the launch of its limited- …
Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
GlobeNewswire
·
April 28, 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a …
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
GlobeNewswire
·
April 28, 2025
MELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET1 imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide …
PDD Holdings Files Annual Report on Form 20-F for Fiscal Year 2024
GlobeNewswire
·
April 28, 2025
DUBLIN and SHANGHAI, April 28, 2025 (GLOBE NEWSWIRE) -- PDD Holdings Inc. (“PDD Holdings” or the “Company”) (NASDAQ: PDD) today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and …
Beachler Investments Announces Progress on Marina Mar Redevelopment Under CEO Andrew Beachler’s Leadership
EIN Presswire
·
April 28, 2025
Waterfront Property in Fort Lauderdale Set for Major Commercial and Lifestyle Transformation MIAMI, FL, UNITED STATES, April 28, 2025 /EINPresswire.com/ -- Beachler Investments, under the leadership of CEO Andrew Beachler, announced significant progress …
Ayushman Skin & Cosmetology Clinic Launches Online Booking Service for Convenient Access to Face and Hair Treatments
EIN Presswire
·
April 28, 2025
NEW DELHI, DWARKA, INDIA, April 28, 2025 /EINPresswire.com/ -- Ayushman Skin …
Cellectis présente une approche non virale d’édition du génome et des innovations avec les base editors à l’ASGCT 2025
GlobeNewswire
·
April 28, 2025
NEW YORK, 28 avr. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS - NASDAQ : CLLS) (la "Société"), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome pour développer des thérapies cellulaires …
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today …
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire
·
April 28, 2025
Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase …
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
GlobeNewswire
·
April 28, 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils …
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
GlobeNewswire
·
April 28, 2025
NEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today …
Portillo’s Announces Plan to Further Strengthen Board Through Cooperation Agreement with Engaged Capital
GlobeNewswire
·
April 28, 2025
CHICAGO, April 28, 2025 (GLOBE NEWSWIRE) -- Portillo’s Inc. (“Portillo’s” or the “Company”) (NASDAQ: PTLO), the fast-casual restaurant concept known for its menu of Chicago-style favorites, today announced that it has entered into a cooperation agreement …
SPAR Group, Inc. Receives Nasdaq Notice of Late Filing of its Form 10-K
GlobeNewswire
·
April 28, 2025
AUBURN HILLS, Mich., April 28, 2025 (GLOBE NEWSWIRE) -- SPAR Group, Inc. (NASDAQ: SGRP) (“SGRP”, “SPAR Group” or the “Company”), a provider of merchandising, marketing and distribution services announced today that it received a notification letter (the “ …
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
GlobeNewswire
·
April 28, 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will …
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
GlobeNewswire
·
April 28, 2025
- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Preclinical synergistic anti-tumor activity of FHD-909 in combination with pembrolizumab and KRAS …
Pool Corporation to Present at the Oppenheimer 20th Annual Industrial Growth Conference
GlobeNewswire
·
April 28, 2025
COVINGTON, La., April 28, 2025 (GLOBE NEWSWIRE) -- Pool Corporation (Nasdaq:POOL) announced today that Melanie M. Hart, Senior Vice President and Chief Financial Officer, will participate in the Oppenheimer 20th Annual Industrial Growth Conference on …
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
GlobeNewswire
·
April 28, 2025
BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that a presentation …
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
GlobeNewswire
·
April 28, 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial …